(Posted By: Josi Creek)
Laboratories and its Massachusetts biotech partner have launched a
final-stage clinical trial of their experimental treatment for multiple
first patient — out of 1,500 needed worldwide — was enrolled last month
in the U.S. The drug, daclizumab, is being developed for monthly
injection under the patient’s skin by North Chicago-based Abbott and
Cambridge-based Biogen Idec.